Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.

EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.

Matching placebo was administered as one capsule per day for 21 days.

Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.